Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Metastatic Colorectal Cancer
Related studies linked through entity extraction aliases.
Biomarker - Panitumumab Response With KRAS Wild Type MCC
- Status
- COMPLETED
- Phase
- NA
Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
- Status
- COMPLETED
- Phase
- PHASE1
Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of IMC-11F8 in Participants With Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project
- Status
- TERMINATED
- Phase
- N/A
Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
- Status
- COMPLETED
- Phase
- PHASE2
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
- Status
- COMPLETED
- Phase
- PHASE2
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
- Status
- COMPLETED
- Phase
- PHASE2
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib
- Status
- UNKNOWN
- Phase
- PHASE2
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2